Pulse Biosciences Net Worth
Pulse Biosciences Net Worth Breakdown | PLSE |
Pulse Biosciences Net Worth Analysis
Pulse Biosciences' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Pulse Biosciences' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Pulse Biosciences' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Pulse Biosciences' net worth analysis. One common approach is to calculate Pulse Biosciences' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Pulse Biosciences' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Pulse Biosciences' net worth. This approach calculates the present value of Pulse Biosciences' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Pulse Biosciences' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Pulse Biosciences' net worth. This involves comparing Pulse Biosciences' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Pulse Biosciences' net worth relative to its peers.
Enterprise Value |
|
To determine if Pulse Biosciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Pulse Biosciences' net worth research are outlined below:
| Pulse Biosciences had very high historical volatility over the last 90 days | |
| Net Loss for the year was (42.21 M) with loss before overhead, payroll, taxes, and interest of (550 K). | |
| Pulse Biosciences currently holds about 14.8 M in cash with (33.04 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.4. | |
| Pulse Biosciences has a poor financial position based on the latest SEC disclosures | |
| Roughly 72.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from finance.yahoo.com: Pulse Biosciences, Inc. Announces Election to Exercise Company Warrants |
Pulse Biosciences Quarterly Good Will |
|
Pulse Biosciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Pulse Biosciences. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Pulse Biosciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Know Pulse Biosciences' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Pulse Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Pulse Biosciences backward and forwards among themselves. Pulse Biosciences' institutional investor refers to the entity that pools money to purchase Pulse Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Westside Investment Management, Inc. | 2024-09-30 | 55 K | Bank Of New York Mellon Corp | 2024-09-30 | 40.3 K | Spotlight Asset Group, Inc. | 2024-06-30 | 40.3 K | Swiss National Bank | 2024-09-30 | 35.9 K | Goldman Sachs Group Inc | 2024-09-30 | 35.7 K | Ubs Asset Mgmt Americas Inc | 2024-09-30 | 33.5 K | Barclays Plc | 2024-09-30 | 30.3 K | Tiaa Trust National Association | 2024-09-30 | 27.3 K | Rhumbline Advisers | 2024-09-30 | 25.8 K | Blackrock Inc | 2024-06-30 | 1.1 M | Vanguard Group Inc | 2024-09-30 | 995.8 K |
Follow Pulse Biosciences' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 992.88 M.Market Cap |
|
Project Pulse Biosciences' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.89) | (0.94) | |
| Return On Capital Employed | (0.96) | (1.00) | |
| Return On Assets | (0.82) | (0.86) | |
| Return On Equity | (0.86) | (0.81) |
When accessing Pulse Biosciences' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Pulse Biosciences' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Pulse Biosciences' profitability and make more informed investment decisions.
Please note, the presentation of Pulse Biosciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Pulse Biosciences' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Pulse Biosciences' management manipulating its earnings.
Evaluate Pulse Biosciences' management efficiency
Pulse Biosciences has return on total asset (ROA) of (0.3815) % which means that it has lost $0.3815 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7028) %, meaning that it created substantial loss on money invested by shareholders. Pulse Biosciences' management efficiency ratios could be used to measure how well Pulse Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of January 4, 2025, Return On Tangible Assets is expected to decline to -0.94. In addition to that, Return On Capital Employed is expected to decline to -1. At present, Pulse Biosciences' Debt To Assets are projected to increase slightly based on the last few years of reporting. The current year's Fixed Asset Turnover is expected to grow to 0.11, whereas Net Tangible Assets are forecasted to decline to about 26.1 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.06 | 1.01 | |
| Tangible Book Value Per Share | 0.95 | 1.49 | |
| Enterprise Value Over EBITDA | (11.74) | (12.33) | |
| Price Book Value Ratio | 15.24 | 16.01 | |
| Enterprise Value Multiple | (11.74) | (12.33) | |
| Price Fair Value | 15.24 | 16.01 | |
| Enterprise Value | 25.1 M | 26.4 M |
Leadership at Pulse Biosciences emphasizes sustainable growth and financial prudence. Our analysis evaluates how these priorities impact the stock's performance in the market.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Pulse Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Pulse Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Pulse Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Pulse Biosciences Corporate Filings
F4 | 20th of December 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 19th of December 2024 Other Reports | ViewVerify | |
8K | 6th of December 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10Q | 19th of August 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
Pulse Biosciences Earnings per Share Projection vs Actual
Pulse Biosciences Corporate Management
| Patty Perla | Vice Resources | Profile | |
| Sandra Gardiner | CFO Admin | Profile | |
| JD Esq | General Secretary | Profile | |
| Gansevoort MD | Chief Officer | Profile | |
| Niv MD | Chief Surgery | Profile | |
| Richard Nuccitelli | Chief Officer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pulse Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Pulse Stock refer to our How to Trade Pulse Stock guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pulse Biosciences. If investors know Pulse will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pulse Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Pulse Biosciences is measured differently than its book value, which is the value of Pulse that is recorded on the company's balance sheet. Investors also form their own opinion of Pulse Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Pulse Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pulse Biosciences' market value can be influenced by many factors that don't directly affect Pulse Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pulse Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pulse Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pulse Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.